Erik Rytting, PhD, MS

Director, Nanomedicine Laboratory

Calculated based on number of publications stored in Pure and citations from Scopus

Research activity per year

Personal profile

Research Strategic Pillar

Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):

Research interests

We are working to develop improved drug delivery strategies, with special emphasis on drug and nanoparticle transport across the placenta in order to address the needs of pregnant women requiring medical therapy or diagnostics, and to answer questions regarding the safety of medication during pregnancy in relation to fetal development. Maintenance of the mother's health promotes successful pregnancy outcomes, and this may require pharmacologic therapy for pregnant women with asthma, diabetes, epilepsy, HIV, or other illnesses. For a small but significant percentage of women, cancer is discovered during pregnancy, which presents a special challenge to adequately treat the cancer and simultaneously protect the baby's growth within the womb. In some instances, fetal therapy is required to treat conditions such as fetal arrhythmias or congenital adrenal hyperplasia; these cases may require drug delivery to the fetus while trying to reduce unwanted side effects in the mother.

Education/Academic qualification

B.S. Chemical Engineering, Brigham Young University, Provo, Utah

Ph.D. Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas

Research Strategic Pillar Keywords

  • Life Span Health


Dive into the research topics where Erik Rytting is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or